Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

About this Publication
Title
Stratifying Ovarian Cancer Risk Using Personal Health Data.
Pubmed ID
33693347 (View this publication on the PubMed website)
Digital Object Identifier
Publication
Front Big Data. 2019; Volume 2: Pages 24
Authors
Hart GR, Nartowt BJ, Muhammad W, Liang Y, Huang GS, Deng J
Affiliations
  • Department of Therapeutic Radiology, School of Medicine, Yale University, New Haven, CT, United States.
  • Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, Yale University, New Haven, CT, United States.
Abstract

Purpose: Screening the general population for ovarian cancer is not recommended by every major medical or public health organization because the harms from screening outweigh the benefit it provides. To improve ovarian cancer detection and survival many are looking at high-risk populations who would benefit from screening. Methods: We train a neural network on readily available personal health data to predict and stratify ovarian cancer risk. We use two different datasets to train our network: The National Health Interview Survey and Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Results: Our model has an area under the receiver operating characteristic curve of 0.71. We further demonstrate how the model could be used to stratify patients into different risk categories. A simple 3-tier scheme classifies 23.8% of those with cancer and 1.0% of those without as high-risk similar to genetic testing, and 1.1% of those with cancer and 24.4% of those without as low risk. Conclusion: The developed neural network offers a cost-effective and non-invasive way to identify those who could benefit from targeted screening.

Related CDAS Studies
Related CDAS Projects